CA3054616A1 - Cxcr2 antibodies and uses thereof - Google Patents

Cxcr2 antibodies and uses thereof Download PDF

Info

Publication number
CA3054616A1
CA3054616A1 CA3054616A CA3054616A CA3054616A1 CA 3054616 A1 CA3054616 A1 CA 3054616A1 CA 3054616 A CA3054616 A CA 3054616A CA 3054616 A CA3054616 A CA 3054616A CA 3054616 A1 CA3054616 A1 CA 3054616A1
Authority
CA
Canada
Prior art keywords
seq
set forth
antibody
cxcr2
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3054616A
Other languages
English (en)
French (fr)
Inventor
Charles Reay Mackay
Remy Michel ROBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900656A external-priority patent/AU2017900656A0/en
Application filed by Monash University filed Critical Monash University
Publication of CA3054616A1 publication Critical patent/CA3054616A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3054616A 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof Pending CA3054616A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900656 2017-02-27
AU2017900656A AU2017900656A0 (en) 2017-02-27 CXCR2 antibodies
PCT/IB2018/000253 WO2018154391A1 (en) 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3054616A1 true CA3054616A1 (en) 2018-08-30

Family

ID=63253562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054616A Pending CA3054616A1 (en) 2017-02-27 2018-02-27 Cxcr2 antibodies and uses thereof

Country Status (8)

Country Link
US (1) US11053319B2 (enExample)
EP (1) EP3585816A4 (enExample)
JP (2) JP7562258B2 (enExample)
KR (1) KR102673489B1 (enExample)
CN (1) CN110637034B (enExample)
AU (1) AU2018224391B2 (enExample)
CA (1) CA3054616A1 (enExample)
WO (1) WO2018154391A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES
BR112021001683A2 (pt) * 2018-08-01 2021-05-04 Cephalon, Inc. anticorpos anti-cxcr2 e usos dos mesmos
KR20220092859A (ko) 2019-09-04 2022-07-04 상하이테크 유니버시티 항-cxcr2 항체 및 이의 용도
EP4330286A4 (en) * 2021-04-26 2025-04-16 Kaohsiung Medical University ANTI-CXCR2 ANTIBODIES AND THEIR USES
KR102952495B1 (ko) * 2023-06-28 2026-04-16 (재) 스크립스코리아항체연구원 항-cxcr2 항체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014170317A1 (en) * 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
EP3565596A4 (en) * 2017-01-05 2020-12-16 Brown University PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS
EP3585816A4 (en) 2017-02-27 2020-12-30 Monash University CXCR2 ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
WO2018154391A1 (en) 2018-08-30
JP2020508074A (ja) 2020-03-19
US11053319B2 (en) 2021-07-06
CN110637034A (zh) 2019-12-31
EP3585816A1 (en) 2020-01-01
AU2018224391B2 (en) 2025-06-12
JP2023052023A (ja) 2023-04-11
AU2018224391A1 (en) 2019-09-19
JP7562258B2 (ja) 2024-10-07
CN110637034B (zh) 2023-10-10
KR20190123753A (ko) 2019-11-01
KR102673489B1 (ko) 2024-06-07
EP3585816A4 (en) 2020-12-30
US20190016809A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US20220389114A1 (en) Pd-l1 antibodies binding canine pd-l1
US12071484B2 (en) Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein
KR102497259B1 (ko) Ｌａｇ―３ 항체, 이의 항원-결합 단편 및 이의 약학적 용도
US11053319B2 (en) CXCR2 antibodies and uses thereof
US20190352390A1 (en) Antibodies to il-37
KR20120089346A (ko) 높은 차단 활성을 갖는 항-Ｃ5ａ 결합 부분
US10696741B2 (en) Anti-IL-22R antibodies
CA3239307A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha 1
AU2017258492A1 (en) Interferon beta antibodies and uses thereof
EP4108683A1 (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
CA2898618C (en) Il-11r binding proteins and uses thereof
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
KR20250124805A (ko) Cd24에 대한 항체 및 이의 용도
US20220049003A1 (en) Methods of treating inflammation
HK40126994A (en) Caninized antibodies
HK1253584B (en) Antibody therapeutics that bind cd38

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230216

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241023

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302